For the readers interested in the stock health of Intellia Therapeutics Inc. (NTLA). It is currently valued at $76.50. When the transactions were called off in the previous session, Stock hit the highs of $82.87, after setting-off with the price of $78.245. Company’s stock value dipped to $76.30 during the trading on the day. When the trading was stopped its value was $79.24.
Recently in News on June 4, 2021, Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting. Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidate. You can read further details here
Intellia Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $92.00 on 01/15/21, with the lowest value was $43.86 for the same time period, recorded on 03/05/21.
Intellia Therapeutics Inc. (NTLA) full year performance was 267.79%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Intellia Therapeutics Inc. shares are logging -16.85% during the 52-week period from high price, and 362.52% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $16.54 and $92.00.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1744740 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Intellia Therapeutics Inc. (NTLA) recorded performance in the market was 40.62%, having the revenues showcasing 23.23% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 5.08B, as it employees total of 312 workers.
Specialists analysis on Intellia Therapeutics Inc. (NTLA)
During the last month, 11 analysts gave the Intellia Therapeutics Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 3 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 69.48, with a change in the price was noted +5.10. In a similar fashion, Intellia Therapeutics Inc. posted a movement of +7.14% for the period of last 100 days, recording 1,399,871 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for NTLA is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Trends and Technical analysis: Intellia Therapeutics Inc. (NTLA)
Raw Stochastic average of Intellia Therapeutics Inc. in the period of last 50 days is set at 60.26%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 51.00%. In the last 20 days, the company’s Stochastic %K was 69.45% and its Stochastic %D was recorded 83.23%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 40.62%. Additionally, trading for the stock in the period of the last six months notably improved by 42.64%, alongside a boost of 267.79% for the period of the last 12 months. The shares increased approximately by -8.00% in the 7-day charts and went down by 15.28% in the period of the last 30 days. Common stock shares were driven by 23.23% during last recorded quarter.